Furthermore, PD-L1 overexpression is more prevalent in inflammatory breast cancers (a rare and particularly aggressive form of disease) that are ER (estrogen receptor) negative, basal, and ERBB2 enriched (Bertucci et al., 2015). The gene discussed is ESR1; the disease is inflammatory breast carcinoma.